Back to Journals » Degenerative Neurological and Neuromuscular Disease » Volume 1

Editorial

Authors Lopate G

Published 18 March 2011 Volume 2011:1 Pages 1—2

DOI https://doi.org/10.2147/DNND.S17825



Glenn Lopate
Department of Neurology, Washington University of St. Louis, St. Louis, MO, USA

The proposition to start a new journal is always a difficult one. However, the recent trend of open access journals has allowed publishers to expand the number of journals available to all scientists worldwide. The Directory of Open Access Journals1 lists 522 medical journals and 94 neurological journals, but only one with a focus on neurodegeneration. This new journal, Degenerative Neurological and Neuromuscular Disease, published by Dove Medical Press, will hopefully be able to fill that void. The idea for this journal was inspired by the aging population and the frequent occurrence of neurodegenerative diseases in this large group of patients. According to the United Nations Department of Economic and Social Affairs,2 in 1950 at the global level, 1 in 12 individuals was at least 60 years old and 1 in 20 was at least 65.  By 2050 those numbers are projected to be 1 in 5 over 60 years old and 1 in 6 over 65. A recent PubMed search supports the idea that neurodegenerative diseases are quite common, with almost 600 articles published in 2010 under the search terms degenerative neurological disease or degenerative neuromuscular disease, a 25% increase from the number published 10 years earlier.

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.